On September 26, 2025, Bio‑Techne Corporation (NASDAQ: TECH) announced new advancements in its spatial biology portfolio, including the RNAscope® in situ hybridization (ISH) technology and the Lunaphore COMET™ platform. The announcement, released via PRNewswire from Minneapolis, highlighted the company’s commitment to expanding tools that enable researchers and pathologists to detect RNA and protein biomarkers on the same tissue section.
RNAscope® empowers users to identify clinically relevant biomarkers—such as viral markers, secreted proteins, point mutations, and chromosomal translocations—within routine anatomic pathology workflows. The COMET™ platform offers fully automated, high‑throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multi‑omic workflows and enabling deeper biological insights. Studies presented this fall include IGLL5 detection for B‑cell clonality and a 21‑plex seqIF™ panel for spatial profiling of lymphoid malignancies.
The company will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26–30, 2025, in Long Beach, CA. Bio‑Techne will partner with Leica Biosystems to host a reception, providing attendees the opportunity to explore RNAscope assays on Leica BOND platforms and to experience the COMET™ system in a hands‑on setting.
This announcement underscores Bio‑Techne’s strategy of delivering differentiated, high‑quality life‑science tools across its key growth verticals, reinforcing its position as a leader in spatial biology and supporting the company’s broader focus on innovation and market expansion.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.